M-J Ahn

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Irinotecan and cisplatin demonstrated promising outcomes in extensive-stage small-cell lung cancer. According to the dosage and schedule of irinotecan, efficacy and toxicity profiles showed subtle differences. This study was designed to evaluate efficacy and toxicity of 3-week schedule of irinotecan/cisplatin in patients with previously untreated(More)
  • 1